CA2531023A1 - Glycoconjuges et leur utilisation comme vaccins potentiels contre une infection provoquee par shigella flexneri - Google Patents

Glycoconjuges et leur utilisation comme vaccins potentiels contre une infection provoquee par shigella flexneri Download PDF

Info

Publication number
CA2531023A1
CA2531023A1 CA002531023A CA2531023A CA2531023A1 CA 2531023 A1 CA2531023 A1 CA 2531023A1 CA 002531023 A CA002531023 A CA 002531023A CA 2531023 A CA2531023 A CA 2531023A CA 2531023 A1 CA2531023 A1 CA 2531023A1
Authority
CA
Canada
Prior art keywords
residue
mixture
molecule
nmr
alphalrhap
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002531023A
Other languages
English (en)
Other versions
CA2531023C (fr
Inventor
Armelle Phalipon
Farida Nato
Laurence Mulard
Philippe Sansonetti
Francoise Baleux
Frederic Belot
Cyrille Grandjean
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Centre National de la Recherche Scientifique CNRS
Institut Pasteur de Lille
Institut National de la Sante et de la Recherche Medicale INSERM
Original Assignee
Institut Pasteur
Inserm (Institut National De La Sante Et De La Recherche Medicale)
Centre National De La Recherche Scientifique
Armelle Phalipon
Farida Nato
Laurence Mulard
Philippe Sansonetti
Francoise Baleux
Frederic Belot
Cyrille Grandjean
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from CA002434685A external-priority patent/CA2434685A1/fr
Priority claimed from CA002434668A external-priority patent/CA2434668A1/fr
Application filed by Institut Pasteur, Inserm (Institut National De La Sante Et De La Recherche Medicale), Centre National De La Recherche Scientifique, Armelle Phalipon, Farida Nato, Laurence Mulard, Philippe Sansonetti, Francoise Baleux, Frederic Belot, Cyrille Grandjean filed Critical Institut Pasteur
Priority to CA2531023A priority Critical patent/CA2531023C/fr
Publication of CA2531023A1 publication Critical patent/CA2531023A1/fr
Application granted granted Critical
Publication of CA2531023C publication Critical patent/CA2531023C/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
CA2531023A 2003-07-04 2004-07-02 Glycoconjuges et leur utilisation comme vaccins potentiels contre une infection provoquee par shigella flexneri Active CA2531023C (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CA2531023A CA2531023C (fr) 2003-07-04 2004-07-02 Glycoconjuges et leur utilisation comme vaccins potentiels contre une infection provoquee par shigella flexneri

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
CA002434685A CA2434685A1 (fr) 2003-07-04 2003-07-04 Nouvelle approche d'elaboration de glycopeptides a base de polysaccharide o-specifique du serotype 2a de shigella flexneri
CA2,434,685 2003-07-04
CA002434668A CA2434668A1 (fr) 2003-07-04 2003-07-07 Nouvelle approche pour concevoir des glycopeptides a base de o-specifique polysaccharide de shigella flexneri serotype 2a
CA2,434,668 2003-07-07
CA2531023A CA2531023C (fr) 2003-07-04 2004-07-02 Glycoconjuges et leur utilisation comme vaccins potentiels contre une infection provoquee par shigella flexneri
PCT/IB2004/002657 WO2005003775A2 (fr) 2003-07-04 2004-07-02 Glycoconjuges et leur utilisation comme vaccins potentiels contre une infection provoquee par shigella flexneri

Publications (2)

Publication Number Publication Date
CA2531023A1 true CA2531023A1 (fr) 2005-01-13
CA2531023C CA2531023C (fr) 2013-04-30

Family

ID=36141766

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2531023A Active CA2531023C (fr) 2003-07-04 2004-07-02 Glycoconjuges et leur utilisation comme vaccins potentiels contre une infection provoquee par shigella flexneri

Country Status (1)

Country Link
CA (1) CA2531023C (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10517936B2 (en) 2013-01-04 2019-12-31 OBI Pharma., Inc. Vaccines with higher carbohydrate antigen density and novel saponin adjuvant

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10517936B2 (en) 2013-01-04 2019-12-31 OBI Pharma., Inc. Vaccines with higher carbohydrate antigen density and novel saponin adjuvant
US11752204B2 (en) 2013-01-04 2023-09-12 Obi Pharma Inc. Vaccines with higher carbohydrate antigen density and novel saponin adjuvant

Also Published As

Publication number Publication date
CA2531023C (fr) 2013-04-30

Similar Documents

Publication Publication Date Title
US9446109B2 (en) Glycoconjugates and their use as potential vaccines against infection by Shigella flexneri
US11191822B2 (en) Pneumococcal polysaccharide-protein conjugate composition
Zhao et al. Conjugation of synthetic trisaccharide of Staphylococcus aureus type 8 capsular polysaccharide elicits antibodies recognizing intact bacterium
US10087242B2 (en) Glycoconjugates and use thereof as vaccine against Shigella flexneri serotype 3a and X
AU2012292430B2 (en) Oligosaccharides and oligosaccharide-protein conjugates derived from Clostridium difficile polysaccaride PS-I, methods of synthesis and uses thereof, in particular as vaccines and diagnostic tools
US10500262B2 (en) Synthetic antigen constructs against Campylobacter jejuni
EP2911698B1 (fr) Glycoconjugués et leur utilisation comme vaccins potentiels contre une infection provoquée par des bactéries shigella flexneri
US20240024489A1 (en) Protected disaccharides, their process of preparation and their use in the synthesis of zwitterionic oligosaccharides, and conjugates thereof
CA2531023C (fr) Glycoconjuges et leur utilisation comme vaccins potentiels contre une infection provoquee par shigella flexneri
EP1000076A1 (fr) VACCIN CONJUGUE HEXADECASACCHARIDE-PROTEINE CONTRE $i(SHIGELLA DYSENTERIAE) DE TYPE 1
EP3269385A1 (fr) Composition de conjugués de polysaccharide-protéine pneumococcique
CA2434685A1 (fr) Nouvelle approche d'elaboration de glycopeptides a base de polysaccharide o-specifique du serotype 2a de shigella flexneri
WO2023168520A1 (fr) Prévention/traitement d'une infection par pseudomonas aeruginosa
US20190167779A1 (en) Synthetic Antigen Constructs Against Campylobacter Jejuni
CA2511084A1 (fr) Conjugues carbohydrate-phosphorylcholine et utilisations vaccinales, therapeutiques et diagnostiques connexes

Legal Events

Date Code Title Description
EEER Examination request